Abstract
Multidrug resistance (MDR) is explained by drug transporters with a drug-handling activity. Despite much work, MDR remains multifaceted, and several conditions are required to generate drug resistance. The drug pumping was conceptually described using a kinetic, i.e., temporal, approach. The re-emergence of physical biology has allowed us to take into account new parameters focusing on the notion of space. This, in turn, has given us important clues regarding the process whereby drug and transporter interact. We will demonstrate that the likelihood of drug-transporter meeting (i.e., the affinity) and thus interaction are also driven by the mechanical interaction between drug molecular weight (MW) and the membrane mechanical properties. This should allow us to mechanically control drug delivery.
Similar content being viewed by others
Notes
Note that “spatial organization of a system” does refer also to dimensions that we will see are crucial to drug transporter meeting probability. Indeed, diffusion properties are different in 1, 2 or 3 dimensions.
The efficiency defined at the molecular levels is referred as the number of products created per unit of time.
Note that in the following text, surface pressure or tension will be used without conceptual difference. In both cases they refer to the mechanical packing of lipids in membrane leaflets.
References
Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, Harrell PM, Trinh YT, Zhang Q, Urbatsch IL, Chang G (2009) Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323:1718–1722
Ambudkar SV, Kim IW, Sauna ZE (2006) The power of the pump: mechanisms of action of P-glycoprotein (ABCB1). Eur J Pharm Sci 27:392–400
Ayrton A, Morgan P (2008) Role of transport proteins in drug discovery and development: a pharmaceutical perspective. Xenobiotica 38:676–708
Biedler JL, Riehm H (1970) Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res 30:1174–1184
Borgnia MJ, Eytan GD, Assaraf YG (1996) Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. J Biol Chem 271:3163–3171
Borst P, Elferink RO (2002) Mammalian ABC transporters in health and disease. Annu Rev Biochem 71:537–592
Buxbaum E (1999) Co-operating ATP sites in the multiple drug resistance transporter Mdr1. Eur J Biochem 265:54–63
Chan LM, Lowes S, Hirst BH (2004) The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci 21:25–51
Chang XB (2007) A molecular understanding of ATP-dependent solute transport by multidrug resistance-associated protein MRP1. Cancer Metastasis Rev 26:15–37
Dano K (1973) Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochim Biophys Acta 323:466–483
Devaux PF (2000) Is lipid translocation involved during endo and exocytosis? Biochimie 82:497–509
Drews J (2003) Strategic trends in the drug industry. Drug Discov Today 8:411–420
Eytan GD, Regev R, Oren G, Hurwitz CD, Assaraf YG (1997) Efficiency of P-glycoprotein-mediated exclusion of rhodamine dyes from multidrug-resistant cells is determined by their passive transmembrane movement rate. Eur J Biochem 248:104–112
Farge E (1995) Increased vesicle endocytosis due to an increase in the plasma membrane phosphatidylserine concentration. Biophys J 69:2501–2506
Farge E, Devaux PF (1992) Shape changes of giant liposomes induced by an asymmetric transmembrane distribution of phospholipids. Biophys J 61:347–357
Farge E, Bitbol M, Devaux PF (1990) Biomembrane elastic response to intercalation of amphiphiles. Eur Biophys J 19:69–72
Farge E, Ojcius DM, Subtil A, Dautry-Varsat A (1999) Enhancement of endocytosis due to aminophospholipid transport across the plasma membrane of living cells. Am J Physiol 276:C725–C733
Fromm MF (2003) Importance of P-glycoprotein for drug disposition in humans. Eur J Clin Invest 33(Suppl 2):6–9
Gleeson MP (2008) Generation of a set of simple, interpretable ADMET rules of thumb. J Med Chem 51:817–834
Gombar VK, Polli JW, Humphreys JE, Wring SA, Serabjit-Singh CS (2004) Predicting P-glycoprotein substrates by a quantitative structure-activity relationship model. J Pharm Sci 93:957–968
Higgins CF (2007) Multiple molecular mechanisms for multidrug resistance transporters. Nature 446:749–757
Hochmuth FM, Shao JY, Dai J, Sheetz MP (1996) Deformation and flow of membrane into tethers extracted from neuronal growth cones. Biophys J 70:358–369
Hou TJ, Xu XJ (2003) ADME evaluation in drug discovery. 3. Modeling blood–brain barrier partitioning using simple molecular descriptors. J Chem Inf Comput Sci 43:2137–2152
Israelachvili JN, Marcelja S, Horn RG (1980) Physical principles of membrane organization. Q Rev Biophys 13:121–200
Juliano RL, Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152–162
Kim H, Barroso M, Samanta R, Greenberger L, Sztul E (1997) Experimentally induced changes in the endocytic traffic of P-glycoprotein alter drug resistance of cancer cells. Am J Physiol 273:C687–C702
Kimura Y, Morita SY, Matsuo M, Ueda K (2007) Mechanism of multidrug recognition by MDR1/ABCB1. Cancer Sci 98:1303–1310
Koval M, Pagano RE (1991) Intracellular transport and metabolism of sphingomyelin. Biochim Biophys Acta 1082:113–125
Lange Y, Swaisgood MH, Ramos BV, Steck TL (1989) Plasma membranes contain half the phospholipid and 90% of the cholesterol and sphingomyelin in cultured human fibroblasts. J Biol Chem 264:3786–3793
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46:3–26
Martin C, Berridge G, Higgins CF, Mistry P, Charlton P, Callaghan R (2000a) Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol 58:624–632
Martin C, Berridge G, Mistry P, Higgins C, Charlton P, Callaghan R (2000b) Drug binding sites on P-glycoprotein are altered by ATP binding prior to nucleotide hydrolysis. Biochemistry 39:11901–11906
Martin C, Higgins CF, Callaghan R (2001) The vinblastine binding site adopts high- and low-affinity conformations during a transport cycle of P-glycoprotein. Biochemistry 40:15733–15742
Okabe M, Szakacs G, Reimers MA, Suzuki T, Hall MD, Abe T, Weinstein JN, Gottesman MM (2008) Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters. Mol Cancer Ther 7:3081–3091
Oprea TI (2002) Current trends in lead discovery: are we looking for the appropriate properties? Mol Divers 5:199–208
Palm K, Stenberg P, Luthman K, Artursson P (1997) Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm Res 14:568–571
Proudfoot JR (2002) Drugs, leads, and drug-likeness: an analysis of some recently launched drugs. Bioorg Med Chem Lett 12:1647–1650
Quinn RJ, Carroll AR, Pham NB, Baron P, Palframan ME, Suraweera L, Pierens GK, Muresan S (2008) Developing a drug-like natural product library. J Nat Prod 71:464–468
Rauch C (2009a) On the relationship between drug’s size, cell membrane mechanical properties and high levels of multi drug resistance: a comparison to published data. Eur Biophys J 38:537–546
Rauch C (2009b) Toward a mechanical control of drug delivery. On the relationship between Lipinski’s 2nd rule and cytosolic pH changes in doxorubicin resistance levels in cancer cells: a comparison to published data. Eur Biophys J 38:829–846
Rauch C, Farge E (2000) Endocytosis switch controlled by transmembrane osmotic pressure and phospholipid number asymmetry. Biophys J 78:3036–3047
Rauch C, Pluen A (2007) Multi drug resistance-dependent “vacuum cleaner” functionality potentially driven by the interactions between endocytosis, drug size and Pgp-like transporters surface density. Eur Biophys J 36:121–131
Raucher D, Sheetz MP (1999) Characteristics of a membrane reservoir buffering membrane tension. Biophys J 77:1992–2002
Regev R, Eytan GD (1997) Flip-flop of doxorubicin across erythrocyte and lipid membranes. Biochem Pharmacol 54:1151–1158
Roepe PD (1998) The P-glycoprotein efflux pump: how does it transport drugs? J Membr Biol 166:71–73
Roepe PD, Martiney JA (1999) Are ion-exchange processes central to understanding drug-resistance phenomena? Trends Pharmacol Sci 20:62–65
Roepe PD, Wei LY, Cruz J, Carlson D (1993) Lower electrical membrane potential and altered pHi homeostasis in multidrug-resistant (MDR) cells: further characterization of a series of MDR cell lines expressing different levels of P-glycoprotein. Biochemistry 32:11042–11056
Roepe PD, Wei LY, Hoffman MM, Fritz F (1996) Altered drug translocation mediated by the MDR protein: direct, indirect, or both? J Bioenerg Biomembr 28:541–555
Romsicki Y, Sharom FJ (1998) The ATPase and ATP-binding functions of P-glycoprotein—modulation by interaction with defined phospholipids. Eur J Biochem 256:170–178
Rosenberg MF, Velarde G, Ford RC, Martin C, Berridge G, Kerr ID, Callaghan R, Schmidlin A, Wooding C, Linton KJ, Higgins CF (2001) Repacking of the transmembrane domains of P-glycoprotein during the transport ATPase cycle. EMBO J 20:5615–5625
Rudnick J, Gaspari G (2004) Elements of random walk. Cambridge University Press, Cambridge
Santai CT, Fritz F, Roepe PD (1999) Effects of ion gradients on H+ transport mediated by human MDR 1 protein. Biochemistry 38:4227–4234
Sauna ZE, Ambudkar SV (2000) Evidence for a requirement for ATP hydrolysis at two distinct steps during a single turnover of the catalytic cycle of human P-glycoprotein. Proc Natl Acad Sci USA 97:2515–2520
Schinkel AH (1999) P-Glycoprotein, a gatekeeper in the blood–brain barrier. Adv Drug Deliv Rev 36:179–194
Sehested M, Skovsgaard T, van Deurs B, Winther-Nielsen H (1987a) Increase in nonspecific adsorptive endocytosis in anthracycline- and vinca alkaloid-resistant Ehrlich ascites tumor cell lines. J Natl Cancer Inst 78:171–179
Sehested M, Skovsgaard T, van Deurs B, Winther-Nielsen H (1987b) Increased plasma membrane traffic in daunorubicin resistant P388 leukaemic cells. Effect of daunorubicin and verapamil. Br J Cancer 56:747–751
Seifert U, Berndl K, Lipowsky R (1991) Shape transformations of vesicles: phase diagram for spontaneous-curvature and bilayer-coupling models. Phys Rev A 44:1182–1202
Seigneuret M, Devaux PF (1984) ATP-dependent asymmetric distribution of spin-labeled phospholipids in the erythrocyte membrane: relation to shape changes. Proc Natl Acad Sci USA 81:3751–3755
Seigneuret M, Zachowski A, Hermann A, Devaux PF (1984) Asymmetric lipid fluidity in human erythrocyte membrane: new spin-label evidence. Biochemistry 23:4271–4275
Shapiro AB, Ling V (1995) Reconstitution of drug transport by purified P-glycoprotein. J Biol Chem 270:16167–16175
Shapiro AB, Ling V (1997) Extraction of Hoechst 33342 from the cytoplasmic leaflet of the plasma membrane by P-glycoprotein. Eur J Biochem 250:122–129
Shapiro AB, Corder AB, Ling V (1997) P-glycoprotein-mediated Hoechst 33342 transport out of the lipid bilayer. Eur J Biochem 250:115–121
Sharom FJ, Lugo MR, Eckford PD (2005) New insights into the drug binding, transport and lipid flippase activities of the p-glycoprotein multidrug transporter. J Bioenerg Biomembr 37:481–487
Shilling RA, Venter H, Velamakanni S, Bapna A, Woebking B, Shahi S, van Veen HW (2006) New light on multidrug binding by an ATP-binding-cassette transporter. Trends Pharmacol Sci 27:195–203
Simon S (2001) The multiple mechanisms of multidrug resistance and cellular pH. Novartis Found Symp 240:269–281 (discussion 282–9)
Simon S, Roy D, Schindler M (1994) Intracellular pH and the control of multidrug resistance. Proc Natl Acad Sci USA 91:1128–1132
van Meer G (1989) Lipid traffic in animal cells. Annu Rev Cell Biol 5:247–275
Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD (2002) Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 45:2615–2623
Walker JE, Saraste M, Runswick MJ, Gay NJ (1982) Distantly related sequences in the alpha- and beta-subunits of ATP synthase, myosin, kinases and other ATP-requiring enzymes and a common nucleotide binding fold. EMBO J 1:945–951
Zhang Y, Benet LZ (2001) The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 40:159–168
Acknowledgments
This work has been supported by the Medical Research Council (RA3805) and the University of Nottingham (NRF4305). Vasiliki Panagiotopoulou is supported by the Marie Curie early stage training network MMBNOTT. Finally we also thank Holly Broom (3rd Year veterinary student) for helping us re-read the paper and suggesting some modifications.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Panagiotopoulou, V., Richardson, G., Jensen, O.E. et al. On a biophysical and mathematical model of Pgp-mediated multidrug resistance: understanding the “space–time” dimension of MDR. Eur Biophys J 39, 201–211 (2010). https://doi.org/10.1007/s00249-009-0555-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00249-009-0555-5